Moderna, Inc. — Director's Dealing 2022

Mar 3, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2022-03-01

Reporting Person: Klinger Shannon Thyme (Chief Legal Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-01	Stock Option (Right to Buy)	$149.52	A	15091	Acquired	2032-03-01	Common Stock (15091)	Direct
2022-03-01	Restricted Stock Units	$0	A	3721	Acquired		Common Stock (3721)	Direct

Footnotes

F1: 25% of this option will vest and become exercisable on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F2: 25% of the shares subject to this restricted stock unit award will vest on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.